1. Academic Validation
  2. The renal urodilatin system: clinical implications

The renal urodilatin system: clinical implications

  • Cardiovasc Res. 2001 Aug 15;51(3):450-62. doi: 10.1016/s0008-6363(01)00331-5.
W Forssmann 1 M Meyer K Forssmann
Affiliations

Affiliation

  • 1 IPF PharmaCeuticals GmbH, An-Institute of Hannover Medical School, Feodor Lynen-Strasse 31, D-30 625, Hannover, Germany. wgforssmann@gmx.de
Abstract

A renal natriuretic peptide and the 'renal urodilatin system' were identified after the observation that immunoassayable ANP in urine may not be identical to the circulating cardiac hormone ANP, which is a peptide of 28 Amino acids. Urodilatin (INN: Ularitide) is a natriuretic peptide isolated from human urine and belongs to the family of A-type natriuretic Peptides. Urodilatin is differentially processed to a peptide of 32 Amino acids from the same precursor as ANP. It is synthesized in kidney tubular cells and secreted luminally. After secretion from epithelial cells of the distal and/or connecting tubules, Urodilatin interacts downstream at distal segments of the nephron with luminally located receptors whereby it regulates Na(+) and water reabsorption. Thus, the physiological function of the renal Urodilatin system can be described as a paracrine intrarenal regulator for Na(+) and water homeostasis, considering Urodilatin as a real diuretic-natriuretic regulatory peptide. However, the regulation upon which the Urodilatin secretion depends is still not clear. Since Urodilatin has been discovered, a great number of pharmacological and clinical investigations have been carried out using Urodilatin as a drug for several indications. So far, clinical phase I and II studies for acute renal failure, congestive heart failure, and bronchial asthma have been performed.

Figures
Products